Document And Entity Information
Document And Entity Information - shares | 6 Months Ended | |
Jun. 30, 2021 | Jul. 31, 2021 | |
Document And Entity Information [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Jun. 30, 2021 | |
Document Fiscal Period Focus | Q2 | |
Document Fiscal Year Focus | 2021 | |
Entity Registrant Name | CYBEROPTICS CORP | |
Entity Central Index Key | 0000768411 | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Non-accelerated Filer | |
Entity Common Stock, Shares Outstanding | 7,315,381 | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Current Reporting Status | Yes | |
Entity Shell Company | false | |
Entity File Number | 0-16577 | |
Entity Address, Address Line One | 5900 Golden Hills Drive | |
Entity Address, City or Town | MINNEAPOLIS | |
Entity Address, State or Province | MN | |
Entity Address, Postal Zip Code | 55416 | |
Entity Tax Identification Number | 41-1472057 | |
City Area Code | (763) | |
Local Phone Number | 542-5000 | |
Title of 12(b) Security | Common Stock, no par value | |
Trading Symbol | CYBE | |
Security Exchange Name | NASDAQ | |
Document Transition Report | false | |
Document Quarterly Report | true | |
Entity Incorporation, State or Country Code | MN | |
Entity Interactive Data Current | Yes |
CONDENSED CONSOLIDATED BALANCE
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands | Jun. 30, 2021 | Dec. 31, 2020 |
ASSETS | ||
Cash and cash equivalents | $ 9,567 | $ 8,399 |
Marketable securities | 7,249 | 8,121 |
Accounts receivable, less allowances of $412 at June 30, 2021 and $302 at December 31, 2020 | 22,011 | 14,735 |
Inventories | 23,266 | 20,271 |
Prepaid expenses | 686 | 686 |
Other current assets | 1,044 | 890 |
Total current assets | 63,823 | 53,102 |
Marketable securities, long-term | 15,230 | 14,052 |
Equipment and leasehold improvements, net | 3,295 | 3,235 |
Intangible assets, net | 383 | 325 |
Goodwill | 1,366 | 1,366 |
Right-of-use assets (operating leases) | 2,334 | 2,621 |
Trade notes receivable, long-term | 271 | 418 |
Deferred tax assets | 4,233 | 4,597 |
Total assets | 90,935 | 79,716 |
LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
Accounts payable | 11,101 | 5,118 |
Advance customer payments | 954 | 823 |
Accrued expenses | 4,165 | 3,893 |
Current operating lease liabilities | 841 | 819 |
Total current liabilities | 17,061 | 10,653 |
Other liabilities | 147 | 134 |
Long-term operating lease liabilities | 2,813 | 3,244 |
Reserve for income taxes | 323 | 157 |
Total liabilities | 20,344 | 14,188 |
Commitments and contingencies | ||
Stockholders’ equity: | ||
Preferred stock, no par value, 5,000,000 shares authorized, none outstanding | 0 | 0 |
Common stock, no par value, 25,000,000 shares authorized, 7,308,001 shares issued and outstanding at June 30, 2021 and 7,294,617 shares issued and outstanding at December 31, 2020 | 38,555 | 37,817 |
Accumulated other comprehensive loss | (1,327) | (1,102) |
Retained earnings | 33,363 | 28,813 |
Total stockholders’ equity | 70,591 | 65,528 |
Total liabilities and stockholders’ equity | $ 90,935 | $ 79,716 |
CONDENSED CONSOLDIATED BALANCE
CONDENSED CONSOLDIATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Thousands | Jun. 30, 2021 | Dec. 31, 2020 |
Statement of Financial Position [Abstract] | ||
Accounts receivable, allowances | $ 412 | $ 302 |
Preferred stock, par value | ||
Preferred stock, shares authorized | 5,000,000 | 5,000,000 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock, par value | ||
Common stock, shares authorized | 25,000,000 | 25,000,000 |
Common stock, shares issued | 7,308,001 | 7,294,617 |
Common stock, shares outstanding | 7,308,001 | 7,294,617 |
CONDENSED CONSOLIDATED STATEMEN
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) - USD ($) shares in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Income Statement [Abstract] | ||||
Revenues | $ 25,204,000 | $ 15,996,000 | $ 42,936,000 | $ 32,425,000 |
Cost of revenues | 14,095,000 | 8,682,000 | 23,448,000 | 17,828,000 |
Gross margin | 11,109,000 | 7,314,000 | 19,488,000 | 14,597,000 |
Research and development expenses | 2,753,000 | 2,182,000 | 5,514,000 | 4,577,000 |
Selling, general and administrative expenses | 4,695,000 | 3,659,000 | 8,583,000 | 7,818,000 |
Income from operations | 3,661,000 | 1,473,000 | 5,391,000 | 2,202,000 |
Interest income and other | 38,000 | 64,000 | 60,000 | 328,000 |
Income before income taxes | 3,699,000 | 1,537,000 | 5,451,000 | 2,530,000 |
Income tax expense | 590,000 | (96,000) | 901,000 | 53,000 |
Net income | $ 3,109,000 | $ 1,633,000 | $ 4,550,000 | $ 2,477,000 |
Net income per share – Basic | $ 0.43 | $ 0.23 | $ 0.62 | $ 0.35 |
Net income per share – Diluted | $ 0.41 | $ 0.22 | $ 0.61 | $ 0.33 |
Weighted average shares outstanding – Basic | 7,299 | 7,198 | 7,296 | 7,177 |
Weighted average shares outstanding – Diluted | 7,517 | 7,447 | 7,490 | 7,407 |
CONDENSED CONSOLIDATED STATEM_2
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Statement of Comprehensive Income [Abstract] | ||||
Net income | $ 3,109 | $ 1,633 | $ 4,550 | $ 2,477 |
Other comprehensive loss before income taxes: | ||||
Foreign currency translation adjustments | 20 | 154 | (127) | (446) |
Unrealized gains (losses) on available-for-sale securities: | ||||
Unrealized gains (losses) on available-for-sale securities | (52) | 121 | (124) | 261 |
Total other comprehensive income (loss) before income taxes | (32) | 275 | (251) | (185) |
Income tax provision | 11 | (25) | 26 | (55) |
Total other comprehensive income (loss) after income taxes | (21) | 250 | (225) | (240) |
Total comprehensive income | $ 3,088 | $ 1,883 | $ 4,325 | $ 2,237 |
CONDENSED CONSOLIDATED STATEM_3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) | 6 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | ||
Net income | $ 4,550,000 | $ 2,477,000 |
Adjustments to reconcile net income to net cash provided by operating activities: | ||
Depreciation and amortization | 1,292,000 | 1,304,000 |
Non-cash operating lease expense | 287,000 | 272,000 |
Provision (recovery) for doubtful accounts | 174,000 | (9,000) |
Deferred taxes | 388,000 | (48,000) |
Foreign currency transaction losses (gains) | 16,000 | (305,000) |
Share-based compensation | 671,000 | 558,000 |
Unrealized (gain) loss on available-for-sale equity security | (12,000) | 18,000 |
Changes in operating assets and liabilities: | ||
Accounts and trade notes receivable | (7,303,000) | 1,357,000 |
Inventories | (3,493,000) | (5,006,000) |
Prepaid expenses and other assets | (117,000) | (782,000) |
Accounts payable | 6,024,000 | 2,666,000 |
Advance customer payments and other | 133,000 | 319,000 |
Accrued expenses | 456,000 | 780,000 |
Operating leases | (409,000) | (395,000) |
Net cash provided by operating activities | 2,657,000 | 3,206,000 |
CASH FLOWS FROM INVESTING ACTIVITIES: | ||
Proceeds from maturities of available-for-sale marketable securities | 6,083,000 | 6,216,000 |
Proceeds from sales of available-for-sale marketable securities | 225,000 | 0 |
Purchases of available-for-sale marketable securities | (6,775,000) | (7,980,000) |
Additions to equipment and leasehold improvements | (936,000) | (477,000) |
Additions to patents | (159,000) | (41,000) |
Net cash used in investing activities | (1,562,000) | (2,282,000) |
CASH FLOWS FROM FINANCING ACTIVITIES: | ||
Proceeds from exercise of stock options | 67,000 | 256,000 |
Tax payments for shares withheld related to stock option exercises | 0 | (420,000) |
Net cash provided by (used in) financing activities | 67,000 | (164,000) |
Effects of exchange rate changes on cash and cash equivalents | 6,000 | 13,000 |
Net increase in cash and cash equivalents | 1,168,000 | 773,000 |
Cash and cash equivalents – beginning of period | 8,399,000 | 5,836,000 |
Cash and cash equivalents – end of period | $ 9,567,000 | $ 6,609,000 |
Interim Reporting
Interim Reporting | 6 Months Ended |
Jun. 30, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Interim Reporting | 1. INTERIM REPORTING: The interim condensed consolidated financial statements of CyberOptics Corporation and its wholly-owned subsidiaries ("we", "us" or "our") presented herein as of June 30, 2021 , and for the month periods ended June 30, 2021 and 2020, are unaudited but, in the opinion of management, include all adjustments, consisting of normal recurring adjustments necessary, for a fair presentation of financial position, results of operations and cash flows for the periods presented. The results of operations for the three and six month periods ended do not necessarily indicate the results to be expected for the full year. The consolidated balance sheet data was derived from audited consolidated financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America ("U.S. GAAP"). The unaudited interim condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and notes thereto contained in our Annual Report on Form 10-K for the year ended . |
Covid-19 Pandemic
Covid-19 Pandemic | 6 Months Ended |
Jun. 30, 2021 | |
Unusual or Infrequent Items, or Both [Abstract] | |
Covid-19 Pandemic | 2 19 Effect of Covid-19 Outbreak on Business Operations A novel strain of coronavirus ("Covid- 19 ") was first identified in December 2019, and in March 2020, the World Health Organization categorized Covid- 19 as a pandemic. The Covid-19 pandemic is affecting our customers, suppliers, service providers and employees to varying degrees, and the ultimate impacts of Covid-19, including the potential impact of known and future variants, on our business, results of operations, liquidity and prospects are not fully known at this time. The Covid- 19 outbreak has not had a significant impact on our business to date. However, the following factors have affected and may continue to affect our business: · Our key factories are located in Minnesota and Singapore. Both of these locations have been subject to government mandated shelter-in-place orders. Because our operations have been deemed essential, we were able to keep our factories up and running while the shelter-in-place mandates were in effect. If the pandemic worsens, it is possible that our operations may not be deemed essential under future government mandated shelter-in-place orders, and we may be required to shut-down factory operations. We have periodically implemented split-shifts for our factory operations to minimize the number of employees in our facilities at any given time, but these measures have not affected our production capacity. Since the start of the pandemic, many of our non-factory employees have spent the majority of their time working remotely. · Sales of some products, mainly our SQ 3000 Multi-Function systems and MX memory module inspection products, require customer acceptance due to performance or other criteria that is considered more than a formality. Most of our customer’s factories have remained open during the Covid- 19 pandemic because they are deemed to be essential under government shelter-in-place mandates. However, global travel restrictions and quarantine measures have hindered our ability to obtain customer acceptances of certain products at various times in 2020. Continuing or new global travel restrictions and quarantine measures could hinder our ability to obtain customer acceptances in a timely manner in the future, and therefore impact the timing of revenue recognition. · We have experienced some supply disruptions due to the Covid- 19 pandemic, mainly from suppliers not deemed essential by shelter-in-place mandates in certain countries. Key supply chain disruptions have been resolved to date. However, supply chain disruptions could increase significantly if the pandemic worsens and continues for an extended period of time. To date, our on-hand inventories have been sufficient to enable us to mitigate supply disruptions. Although we cannot estimate the continuing impact of the Covid-19 outbreak at this time, it may have an adverse effect on our results of future operations, financial position and liquidity for the remainder of 2021 and beyond. United States Covid-19 Relief Legislation On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (the "CARES Act") was signed into law in the United States. The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods and alternative tax credit refunds. The CARES Act also appropriated funds for the Small Business Administration Paycheck Protection Program loans that are forgivable in certain circumstances to promote continued employment. Additional relief packages were passed in December 2020 and March 2021. We have analyzed these pieces of legislation and presently do not believe they will have a material impact on our financial condition, results of operations or liquidity. However, we will continue to monitor the impact these pieces of legislation could have on our business in the future. Singapore Jobs Support Program The Singapore Government implemented a jobs support program in 2020 that was intended to support businesses and encourage retention of employees during the period of economic uncertainty caused by the Covid-19 pandemic. Under the jobs support program, the Singapore Government co-funded a portion of the gross monthly wages paid to local employees, which reduced our operating expenses in the three and six $276,000 and $295,000, |
Recent Accounting Developments
Recent Accounting Developments | 6 Months Ended |
Jun. 30, 2021 | |
Accounting Policies [Abstract] | |
Recent Accounting Developments | 3. RECENT ACCOUNTING DEVELOPMENTS: In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments, No other new accounting pronouncements are expected to have a significant impact on our consolidated financial statements. |
Revenue Recognition
Revenue Recognition | 6 Months Ended |
Jun. 30, 2021 | |
Revenue Recognition [Abstract] | |
Revenue Recognition | 4. REVENUE RECOGNITION: Our revenue performance obligations are primarily satisfied at a point in time and limited revenue streams are satisfied over time as work progresses. The following is a summary of our revenue performance obligations: Three Months Ended June 30, 2021 Three Months Ended June 30, 2020 (In thousands except percentages) Revenues Percent of Revenues Revenues Percent of Revenues Revenue recognized over time $ 695 2.8 % $ 362 2.3 % Revenue recognized at a point in time 24,509 97.2 % 15,634 97.7 % $ 25,204 100.0 % $ 15,996 100.0 % Six Months Ended June 30, 2021 Six Months Ended June 30, 2020 (In thousands except percentages) Revenues Percent of Revenues Revenues Percent of Revenues Revenue recognized over time $ 1,098 2.6 % $ 555 1.7 % Revenue recognized at a point in time 41,838 97.4 % 31,870 98.3 % $ 42,936 100.0 % $ 32,425 100.0 % See Note 11 for additional information regarding disaggregation of revenue. Contract Balances Contract assets consist of unbilled amounts from sales where we recognize the revenue over time and the revenue recognized exceeds the amount billed to the customer at a point in time. Accounts and trade notes receivable are recorded when the right to payment becomes unconditional. Contract liabilities consist of payments received in advance of performance under the contract. Contract liabilities are recognized as revenue when we perform under the contract. The following summarizes our contract assets and contract liabilities: (In thousands) June 30, 2021 December 31, 2020 Contract assets, included in other current assets $ 18 $ 2 Contract liabilities - advance customer payments $ 653 $ 567 Contract liabilities - deferred warranty revenue $ 391 $ 344 Changes in contract assets in the six months ended June 30, 2021 and the six months ended June 30, 2020 resulted from unbilled amounts under sensor product arrangements and longer duration 3D scanning service projects in which revenue is recognized over time. Changes in contract liabilities primarily resulted from reclassification of beginning contract liabilities to revenue as performance obligations were satisfied or from cash received in advance and not recognized as revenue. See Note 9 for changes in contractual obligations related to deferred warranty revenue. Unsatisfied performance obligations for deferred warranty revenue are generally expected to be recognized as revenue over the next one The following summarizes the amounts reclassified from beginning contract liabilities to revenue: Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2021 2020 2021 2020 Amounts reclassified from beginning contract liabilities to revenue $ 120 $ 55 $ 345 $ 95 Amounts reclassified from deferred warranty revenue 98 83 161 183 T otal $ 218 $ 138 $ 506 $ 278 |
Marketable Securities
Marketable Securities | 6 Months Ended |
Jun. 30, 2021 | |
Marketable Securities [Abstract] | |
Marketable Securities | 5. MARKETABLE SECURITIES: Our investments in marketable securities are classified as available-for-sale and consist of the following: June 30, 2021 (In thousands) Cost Unrealized Unrealized Fair Value Short-Term U.S. government and agency obligations $ 3,332 $ 20 $ — $ 3,352 Corporate debt securities and certificates of deposit 3,882 15 — 3,897 Marketable securities – short-term $ 7,214 $ 35 $ — $ 7,249 Long-Term U.S. government and agency obligations $ 9,094 $ 30 $ (10 ) $ 9,114 Corporate debt securities and certificates of deposit 3,452 27 (1 ) 3,478 Asset backed securities 2,572 25 (1 ) 2,596 Equity security 42 — — 42 Marketable securities – long-term $ 15,160 $ 82 $ (12 ) $ 15,230 December 31, 2020 (In thousands) Cost Unrealized Unrealized Fair Value Short-Term U.S. government and agency obligations $ 4,817 $ 36 $ — $ 4,853 Corporate debt securities and certificates of deposit 3,113 21 — 3,134 Asset backed securities 133 1 — 134 Marketable securities – short-term $ 8,063 $ 58 $ — $ 8,121 Long-Term U.S. government and agency obligations $ 7,529 $ 66 $ — $ 7,595 Corporate debt securities and certificates of deposit 3,975 61 (1 ) 4,035 Asset backed securities 2,347 45 — 2,392 Equity security 42 — (12 ) 30 Marketable securities – long-term $ 13,893 $ 172 $ (13 ) $ 14,052 At June 30, 2021 and December 31, 2020, investments in marketable debt securities in an unrealized loss position were as follows: In Unrealized Loss Position For Less Than 12 Months In Unrealized Loss Position For Greater Than 12 Months (In thousands) Fair Value Gross Unrealized Fair Value Gross Unrealized Losses June 30, 2021 U.S. government and agency obligations $ 5,365 $ (10 ) $ — $ — Corporate debt securities and certificates of deposit 1,676 (1 ) — — Asset backed securities 549 (1 ) — — Marketable securities $ 7,590 $ (12 ) $ — $ — December 31, 2020 U.S. government and agency obligations $ 330 $ — $ — $ — Corporate debt securities and certificates of deposit 411 (1 ) — — Marketable securities $ 741 $ ( 1 ) $ — $ — Our investments in marketable debt securities all have maturities of less than five years. Net pre-tax unrealized gains for marketable debt securities of $105,000 at June 30, 2021 and $229,000 at December 31, 2020 have been recorded as a component of accumulated other comprehensive loss in stockholders’ equity. We have determined that the net pre-tax unrealized losses for marketable debt securities at June 30, 2021 and December 31, 2020 were caused by fluctuations in interest rates and are temporary in nature. We review our marketable debt securities to identify and evaluate investments that have indications of possible impairment. Factors considered in determining whether a loss is other-than-temporary include the length of time and extent to which fair value has been less than the cost basis, credit quality and our ability and intent to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value. We received proceeds from the sale of marketable securities o f $ i three and six months ended June 30, 2020 Investments in marketable securities classified as cash equivalents of $6.0 million at June 30, 2021 and $ 1.3 million Cash and marketable securities held by foreign subsidiaries totale d $ m |
Fair Value Measurements
Fair Value Measurements | 6 Months Ended |
Jun. 30, 2021 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | 6 ASUREMENTS: We determine the fair value of our assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. We use a fair value hierarchy with three two 1 active 2 3 The following provides information regarding fair value measurements for our marketable securities as of June 30, 2021 and December 31, 2020 according to the three Fair Value Measurements at June 30, 2021 (In thousands) Balance June 30, 2021 Quoted Prices 1 Significant 2 Significant 3 Marketable securities: U.S. government and agency obligations $ 12,466 $ — $ 12,466 $ — Corporate debt securities and certificates of deposit 7,375 — 7,375 — Asset backed securities 2,596 — 2,596 — Equity security 42 42 — — Total marketable securities $ 22,479 $ 42 $ 22,437 $ — Fair Value Measurements at December 31, 2020 (In thousands) Balance December 31, 2020 Quoted Prices 1 Significant 2 Significant 3 Marketable securities: U.S. government and agency obligations $ 12,448 $ — $ 12,448 $ — Corporate debt securities and certificates of deposit 7,169 — 7,169 — Asset backed securities 2,526 — 2,526 — Equity security 30 30 — — Total marketable securities $ 22,173 $ 30 $ 22,143 $ — During the six months ended June 30, 2021 and the year ended December 31, 2020, we owned no Level 3 securities and there were no transfers within the three level hierarchy. A significant transfer is recognized when the inputs used to value a security have been changed which merit a transfer between the levels of the valuation hierarchy. The fair value for our U.S. government and agency obligations, corporate debt securities and certificates of deposit and asset backed securities are determined based on valuations provided by external investment managers who obtain them from a variety of industry standard data providers. The fair value for our equity security is based on a quoted market price obtained from an active market. The carrying amounts of financial instruments included in cash equivalents approximate their related fair values due to the short-term maturities of those instruments. See Note 5 for additional information regarding our investments in marketable securities. Non-financial assets such as equipment and leasehold improvements, goodwill and intangible assets and right-of-use assets for operating leases are subject to non-recurring fair value measurements if they are deemed impaired. We had no re-measurements of non-financial assets to fair value in the six months ended June 30, 2021 or the six months ended June 30, 2020. The fair value for trade notes receivable is based on discounted future cash flows using current interest rates that would be offered for a similar transaction to a similarly situated customer. The difference between the carrying amount and estimated fair value for trade notes receivable is immaterial. If measured at fair value in the financial statements, these financial instruments would be classified as Level 3 in the fair value hierarchy. At June 30, 2021, our trade notes receivable were deemed to be fully collectible, and no trade notes receivable were past due more than 90 days or in a non-accrual status with respect to interest income. |
Share-Based Compensation
Share-Based Compensation | 6 Months Ended |
Jun. 30, 2021 | |
Share-based Compensation [Abstract] | |
Share-Based Compensation | 7 We have three share-based compensation plans that are administered by the Compensation Committee of the Board of Directors. We have (a) an Employee Stock Incentive Plan for officers, other employees, consultants and independent contractors under which we have granted options and restricted stock units to officers and other employees, (b) an Employee Stock Purchase Plan under which shares of our common stock may be acquired by employees at discounted prices, and (c) a Non-Employee Director Stock Plan that provides for automatic grants of restricted shares of our common stock to non-employee directors. New shares of our common stock are issued upon stock option exercises, vesting of restricted stock units, issuances of shares to board members and issuances of shares under the Employee Stock Purchase Plan. Employee Stock Incentive Plan As of , there were 124,501 shares and expire seven years after the date of grant. Restricted stock units vest over a four year period and entitle the holders to one share of our common stock for each restricted stock unit. Reserved shares underlying outstanding awards, including options and restricted stock units, that are forfeited are available under the Employee Stock Incentive Plan for future grant. Non-Employee Director Stock Plan As of June 30, 2021, there were 36,000 shares of common stock reserved in the aggregate for issuance pursuant to future restricted share grants under our Non-Employee Director Stock Plan and 8,000 shares of common stock reserved in the aggregate for issuance pursuant to outstanding stock option awards under our Non-Employee Director Stock Plan (which previously authorized the granting of stock options to non-employee directors). Under the terms of the plan, each non-employee director receives annual restricted share grants of 2,000 shares of our common stock on the date of each annual meeting at which such director is elected to serve on the board . The annual restricted share grants of common stock vest in four On the date of our 2021 annual meeting, we issued shares of our common stock to our non-employee directors, which were restricted as specified in the Non-Employee Director Stock Plan. The shares granted at the 2021 annual meeting had an aggregate fair market value on the date of grant equal to $ (grant date fair value of $ per share). Stock Option Activity The following is a summary of stock option activity in the six months ended : Options Outstanding Weighted Average Exercise Outstanding, December 31, 2020 419,100 $ 15.22 Exercised (7,875 ) 17.09 Outstanding, June 30, 2021 411,225 $ 15.19 Exercisable, June 30, 2021 286,151 $ 12.90 The intrinsic value of an option is the amount by which the market price of the underlying common stock exceeds the option's exercise price. For options outstanding at , the weighted average remaining contractual term of all outstanding options was 3.12 years and their aggregate intrinsic value was $10.6 million. At , the weighted average remaining contractual term of options that were exercisable was 2.18 years and their aggregate intrinsic value was $8.0 million. The aggregate intrinsic value of stock options exercised was $ in the six months ended June 30, 2021 and $2.1 million in the six months ended June 30, 2020. $ i . No stock options vested in the six months ended June 30, 2021 or the six months ended June 30, 2020. No stock options were granted, forfeited or expired in the six months ended June 30, 2021. Restricted Shares and Restricted Stock Units There wer e 8,000 r The following is a summary of activity in restricted shares and restricted stock units in the : Restricted shares and restricted stock units Shares Weighted Average Grant Date Fair Value Non-vested at December 31, 2020 68,454 $ 21.45 Granted 8,000 27.96 Vested (4,000 ) 28.34 Non-vested at June 30, 2021 72,454 $ 21.79 Employee Stock Purchase Plan We have an Employee Stock Purchase Plan available to eligible U.S. employees. Under the terms of the plan, eligible employees may designat e from 1 % 10% of their compensation to be withheld through payroll deductions, up to a maximum of $6,500 in each plan year, for the purchase of common stock at 85% of the lower of the market price on the first or last day of the offering period (which begins on August 1 shares were purchased under this plan in the six months ended June 30, 2021 or the six months ended June 30, 2020. As of June 30, 2021, 136,971 shares remain available for future purchase under the Employee Stock Purchase Plan. Share-Based Compensation Information All share-based payments to employees and non-employee directors, including grants of stock options, restricted stock units and restricted shares, are required to be recognized as an expense in our consolidated statements of income based on the grant date fair value of the award. We utilize the straight-line method of expense recognition over the award's service period for our graded vesting options. The fair value of stock options has been determined using the Black-Scholes model. We account for the impact of forfeitures related to employee share-based payment arrangements when the forfeitures occur. We have classified employee share-based compensation within our consolidated statements of income in the same manner as our cash-based employee compensation costs. Pre-tax share-based compensation expense in the three months ended June 30, 2021 totaled $337,000, and included $125,000 for stock options, $31,000 for our Employee 57,000 Pre-tax share-based compensation expense in the six months ended June 30, 2021 671,000 248,000 $63,000 for our Employee 247,000 113,000 Pre-tax share-based compensation expense in the three months ended June 30, 2020 totaled $286,000, and included $114,000 for stock options, $25,000 for our Employee Stock Purchase Plan, $101,000 for restricted stock units and $46,000 for restricted shares. Pre-tax share-based compensation expense in the six months ended June 30, 2020 558,000 228,000 48,000 202,000 80,000 At June 30, 2021, the total unrecognized compensation cost related to non-vested share-based compensation arrangements was $2.3 million and the related weighted average period over which such cost is expected to be recognized was 2.51 years. |
Changes In Stockholders' Equity
Changes In Stockholders' Equity | 6 Months Ended |
Jun. 30, 2021 | |
Stockholders' Equity Note [Abstract] | |
Changes In Stockholders' Equity | 8 CHANGES IN STOCKHOLDERS’ EQUITY: A reconciliation of the changes in our stockholders' equity is as follows: Three Months Ended June 30, 2021 Common Stock Accumulated Other Comprehensive Loss Retained Earnings Total Stockholders’ Equity (In thousands) Shares Amount Balance, March 31, 2021 7,299 $ 38,208 $ (1,306 ) $ 30,254 $ 67,156 Exercise of stock options, net of shares exchanged as payment 1 10 — — 10 Share issuances for director compensation 8 — — — — Share-based compensation — 337 — — 337 Other comprehensive loss, net of tax — — (21 ) — (21 ) Net income — — — 3,109 3,109 Balance, June 30, 2021 7,308 $ 38,555 $ (1,327 ) $ 33,363 $ 70,591 Six Months Ended June 30, 2021 Common Stock Accumulated Other Comprehensive Loss Retained Earnings Total Stockholders’ Equity (In thousands) Shares Amount Balance, December 31, 2020 7,295 $ 37,817 $ (1,102 ) $ 28,813 $ 65,528 Exercise of stock options, net of shares exchanged as payment 5 67 — — 67 Share issuances for director compensation 8 — — — — Share-based compensation — 671 — — 671 Other comprehensive loss, net of tax — — (225 ) — (225 ) Net income — — — 4,550 4,550 Balance, June 30, 2021 7,308 $ 38,555 $ (1,327 ) $ 33,363 $ 70,591 Three Months Ended June 30, 2020 : Common Stock Accumulated Other Comprehensive Loss Retained Earnings Total Stockholders’ Equity (In thousands) Shares Amount Balance, March 31, 2020 7,165 $ $ ) $ 23,915 $ 59,035 Exercise of stock options, net of shares exchanged as payment 75 171 — — 171 Tax payments for shares withheld related to stock option exercises (16 ) (420 ) — — (420 ) Share issuances for director compensation — — Share-based compensation 286 — Other comprehensive income, net of tax 250 — 250 Net income — 1,633 1,633 Balance, June 30, 2020 $ 37,053 $ (1,646 ) $ 25,548 $ 60,955 Six Months Ended June 30, 2020 : Common Stock Accumulated Other Comprehensive Loss Retained Earnings Total Stockholders’ Equity (In thousands) Shares Amount Balance, December 31, 2019 7,155 $ $ ) $ 23,071 $ 58,324 Exercise of stock options, net of shares exchanged as payment 85 256 — — 256 Tax payments for shares withheld related to stock option exercises (16 ) (420 ) — — (420 ) Share issuances for director compensation — — Share-based compensation 558 — Other comprehensive income, net of tax (240 ) — (240 ) Net income — 2,477 2,477 Balance, June 30, 2020 $ 37,053 $ (1,646 ) $ 25,548 $ 60,955 |
Other Financial Statement Data
Other Financial Statement Data | 6 Months Ended |
Jun. 30, 2021 | |
Balance Sheet Related Disclosures [Abstract] | |
Other Financial Statement Data | 9. OTHER FINANCIAL STATEMENT DATA: Inventories consisted of the following: (In thousands) June 30, 2021 December 31, 2020 Raw materials and purchased parts $ 14,106 $ 11,903 Work in process 2,103 2,459 Finished goods 5,603 4,208 Demonstration inventories, net 1,454 1,701 Total inventories $ 23,266 $ 20,271 Demonstration inventories are stated at cost less accumulated amortization, generally based on a month useful life. Accumulated amortization for demonstration inventories totaled $2.6 million at June 30, 2021 and million at December 31, 2020. Amortization expense related to demonstration inventories in the three and six months ended June 30, 2021 Accrued expenses consisted of the following: (In thousands) June 30, 2021 December 31, 2020 Wages and benefits $ 2,873 $ 2,768 Warranty liability 920 793 Income taxes payable 208 269 Other 164 63 Total accrued expenses $ 4,165 $ 3,893 Warranty costs: We provide for the estimated cost of product warranties, which cover products for periods ranging from one three years , at the time revenue is recognized. While we engage in extensive product quality programs and processes, including actively monitoring and evaluating the quality of components provided by suppliers, warranty obligations do arise. These obligations are affected by product failure rates, the costs of materials used in correcting product failures and service delivery expenses incurred to make these corrections. If actual product failure rates and material or service delivery costs differ from our estimates, revisions to the estimated warranty liability are required and could be material. At the end of each reporting period, we revise our estimated warranty liability based on these factors. The current portion of our warranty liability is included as a component of accrued expenses. The long-term portion of our warranty liability is included as a component of other liabilities. A reconciliation of the changes in our estimated warranty liability is as follows: Six Months Ended June 30, (In thousands) 2021 2020 Balance at beginning of period $ 839 $ 798 Accrual for warranties 527 429 Warranty revision 3 9 Settlements made during the period (392 ) (474 ) Balance at end of period 977 762 Current portion of estimated warranty liability (920 ) (729 ) Long-term estimated warranty liability $ 57 $ 33 Deferred warranty revenue: The current portion of our deferred warranty revenue is included as a component of advance customer payments. The long-term portion of our deferred warranty revenue is included as a component of other liabilities. A reconciliation of the changes in our deferred warranty revenue is as follows: Six Months Ended June 30, (In thousands) 2021 2020 Balance at beginning of period $ 344 $ 275 Revenue deferrals 268 231 Amortization of deferred revenue (221 ) (183 ) Total deferred warranty revenue 391 323 Current portion of deferred warranty revenue (301 ) (209 ) Long-term deferred warranty revenue $ 90 $ 114 |
Intangible Assets
Intangible Assets | 6 Months Ended |
Jun. 30, 2021 | |
Intangible Assets, Net (Excluding Goodwill) [Abstract] | |
Intangible Assets | 10. INTANGIBLE ASSETS: Intangible assets consist of the following: June 30, 2021 December 31, 2020 (In thousands) Gross Accumulated Net Gross Accumulated Net Patents $ 1,991 $ (1,628 ) $ 363 $ 1,832 $ (1,542 ) $ 290 Software 206 (206 ) — 206 (200 ) 6 Marketing assets and customer relationships 86 (66 ) 20 101 (72 ) 29 Total intangible assets $ 2,283 $ (1,900 ) $ 383 $ 2,139 $ (1,814 ) $ 325 Amortization expense in the three and six months ended June 30, 2021 and June 30, 2020 was as follows: Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2021 2020 2021 2020 Patents $ 44 $ 35 $ 87 $ 73 Software — 7 6 15 Marketing assets and customer relationships 2 3 4 5 Total amortization expense $ 46 $ 45 $ 97 $ 93 Estimated aggregate amortization expense based on current intangible assets for the next four years is expected to be as follows: $96,000 for the remainder of 2021 $158,000 in 2022 $109,000 in 2023 and $20,000 in 2024 |
Revenue Concentrations, Signifi
Revenue Concentrations, Significant Customers And Geographic Areas | 6 Months Ended |
Jun. 30, 2021 | |
Segment Reporting [Abstract] | |
Revenue Concentrations, Significant Customers And Geographic Areas | 11. REVENUE CONCENTRATIONS, SIGNIFICANT CUSTOMERS AND GEOGRAPHIC AREAS The following summarizes our revenue by product line: Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2021 2020 2021 2020 High Precision 3D and 2D Sensors $ 7,131 $ 4,745 $ 13,488 $ 8,867 Inspection and Metrology Systems 12,581 7,661 18,920 16,022 Semiconductor Sensors 5,492 3,590 10,528 7,536 Total $ 25,204 $ 15,996 $ 42,936 $ 32,425 In the six months ended June 30, 2021, sales to significant customer A accounted for 19 % of our total revenues. As of , accounts receivable from significant customer A were $ 2.4 Export revenues as a percentage of total revenues in the three and six months ended June 30, 2021 were 84% and 83%, respectively. Export revenues as a percentage of total revenues in the three and six months ended June 30, 2020 were Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2021 2020 2021 2020 Americas $ 741 $ 97 $ 1,524 $ 497 Europe 3,017 2,369 6,518 4,472 China 8,545 3,954 13,709 7,834 Taiwan 943 763 1,673 2,479 Other Asia 7,541 5,449 11,683 9,129 Other 428 742 577 742 Total export sales $ 21,215 $ 13,374 $ 35,684 $ 25,153 |
Net Income Per Share
Net Income Per Share | 6 Months Ended |
Jun. 30, 2021 | |
Earnings Per Share [Abstract] | |
Net Income Per Share | 12. NET INCOME PER SHARE: Net income per basic share is computed by dividing net incom e by age numbe (In thousands except per share amounts) Net Income Weighted Average Shares Outstanding Per Share Amount Three Months Ended June 30, 2021 Basic $ 3,109 7,299 $ 0.43 Dilutive effect of common equivalent shares — 218 (0.02 ) Dilutive $ 3,109 7,517 $ 0.41 (In thousands except per share amounts) Net Income Weighted Average Shares Outstanding Per Share Amount Three Months Ended June 30, 2020 Basic $ 1,633 7,198 $ 0.23 Dilutive effect of common equivalent shares — 249 (0.01 ) Dilutive $ 1,633 7,447 $ 0.22 (In thousands except per share amounts) Net Income Weighted Average Shares Outstanding Per Share Amount Six Months Ended June 30, 2021 Basic $ 4,550 7,296 $ 0.62 Dilutive effect of common equivalent shares — 194 (0.01 ) Dilutive $ 4,550 7,490 $ 0.61 (In thousands except per share amounts) Net Income Weighted Average Shares Outstanding Per Share Amount Six Months Ended June 30, 2020 Basic $ 2,477 7,177 $ 0.35 Dilutive effect of common equivalent shares — 230 (0.02 ) Dilutive $ 2,477 7,407 $ 0.33 Potentially dilutive shares consist of stock options, restricted stock units, restricted shares and purchases of shares under our Employee Stock Purchase Plan. Potentially dilutive shares excluded from the calculations of net income per diluted shar e due to their anti-dilutive effect were as follows: 47,000 shares in the three months ended June 30, 2021 shares in the six months ended June 30, 2021; 34,000 shares in the three months ended June 30, 2020 ; 89,000 shares in the six months ended June 30, 2020 . |
Other Comprehensive Income (Los
Other Comprehensive Income (Loss) | 6 Months Ended |
Jun. 30, 2021 | |
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] | |
Other Comprehensive Income (Loss) | 13. OTHER COMPREHENSIVE INCOME (LOSS): Changes in components of other comprehensive income (loss) and taxes related to items of other comprehensive income (loss) are as follows: Three Months Ended June 30, 2021 Three Months Ended June 30, 2020 (In thousands) Before Tax Tax Effect Net of Tax Amount Before Tax Tax Effect Net of Tax Amount Foreign currency translation adjustments $ 20 $ — $ 20 $ 154 $ — $ 154 Unrealized gains (losses) on available-for-sale securities (52 ) 11 (41 ) 121 (25 ) 96 Other comprehensive income (loss) $ (32 ) $ 11 $ (21 ) $ 275 $ (25 ) $ 250 Six Months Ended June 30, 2021 Six Months Ended June 30, 2020 (In thousands) Before Tax Tax Effect Net of Tax Amount Before Tax Tax Effect Net of Tax Amount Foreign currency translation adjustments $ (127 ) $ — $ (127 ) $ (446 ) $ — $ (446 ) Unrealized gains (losses) (124 ) 26 (98 ) 261 (55 ) 206 Other comprehensive loss $ (251 ) $ 26 $ (225 ) $ (185 ) $ (55 ) $ (240 ) At June 30, 2021 and 2020, components of accumulated other comprehensive loss is as follows: (In thousands) Foreign Available- for-Sale Accumulated Balances at December 31, 2020 $ (1,285 ) $ 183 $ (1,102 ) Other comprehensive loss for the six months ended June 30, 2021 (127 ) (98 ) (225 ) Balances at June 30, 2021 $ (1,412 ) $ 85 $ (1,327 ) (In thousands) Foreign Available- for-Sale Accumulated Balances at December 31, 2019 $ (1,475 ) $ 69 $ (1,406 ) Other comprehensive loss for the six months ended June 30, 2020 (446 ) 206 (240 ) Balances at June 30, 2020 $ (1,921 ) $ 275 $ (1,646 ) |
Income Taxes
Income Taxes | 6 Months Ended |
Jun. 30, 2021 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | 14 We recorded income tax expense of $590,000 in the three months ended June 30, 2021, compared to an income tax benefit of $96,000 in the three months ended June 30, 2020. We recorded income tax expense of $901,000 in the six months ended June 30, 2021 We have significant deferred tax assets as a result of temporary differences between taxable income on our tax returns and U.S. GAAP income, R&D tax credit carry forwards and state net operating loss carry forwards. A deferred tax asset generally represents future tax benefits to be received when temporary differences previously reported in our consolidated financial statements become deductible for income tax purposes, when net operating loss carry forwards could be applied against future taxable income, or when tax credit carry forwards are utilized on our tax returns. We assess the realizability of our deferred tax assets and the need for a valuation allowance based on the guidance provided in current financial accounting standards. Significant judgment is required in determining the realizability of our deferred tax assets. The assessment of whether valuation allowances are required considers, among other matters, the nature, frequency and severity of any current and cumulative losses, forecasts of future profitability, the duration of statutory carry forward periods, our experience with loss carry forwards not expiring unused and tax planning alternatives. In analyzing the need for valuation allowances, we first considered our history of cumulative operating results for income tax purposes over the past three years in each of the tax jurisdictions in which we operate, our financial performance in recent quarters, statutory carry forward periods and tax planning alternatives. In addition, we considered both our near-term and long-term financial outlook. After considering all available evidence (both positive and negative), we concluded that recognition of valuation allowances for substantially all of our U.S. and Singapore based deferred tax assets was not required at June 30, 2021 or December 31, 2020. The Inland Revenue Authority of Singapore has initiated a routine compliance review of our 2018 income tax return. We presently anticipate that the outcome of this audit will not have a significant impact on our financial position or results of operations. |
Contingencies
Contingencies | 6 Months Ended |
Jun. 30, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | |
Contingencies | 15 We are periodically a defendant in miscellaneous lawsuits, claims and disputes in the ordinary course of business. While the outcome of these matters cannot be predicted with certainty, management presently believes the disposition of these matters will not have a material effect on our financial position, results of operations or cash flows. In the normal course of business to facilitate sales of our products and services, we at times indemnify other parties, including customers, with respect to certain matters. In these instances, we have agreed to hold the other parties harmless against losses arising out of intellectual property infringement or other types of claims. These agreements may limit the time within which an indemnification claim can be made, and almost always limits the amount of the claim. It is not possible to determine the maximum potential amount of exposure under these indemnification agreements due to the limited history of prior indemnification claims and the unique facts and circumstances involved in each particular agreement. Historically, payments made, if any, under these agreements have not had a material impact on our operating results, financial position or cash flows. However, there can be no assurance that intellectual property infringement and other claims against us or parties we have indemnified will not have a greater impact in the future. |
Recent Accounting Developments
Recent Accounting Developments (Policies) | 6 Months Ended |
Jun. 30, 2021 | |
Accounting Policies [Abstract] | |
Recent Accounting Developments | In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments, No other new accounting pronouncements are expected to have a significant impact on our consolidated financial statements. |
Revenue Recognition (Tables)
Revenue Recognition (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Revenue Recognition [Abstract] | |
Summary of revenue performance obligations | The following is a summary of our revenue performance obligations: Three Months Ended June 30, 2021 Three Months Ended June 30, 2020 (In thousands except percentages) Revenues Percent of Revenues Revenues Percent of Revenues Revenue recognized over time $ 695 2.8 % $ 362 2.3 % Revenue recognized at a point in time 24,509 97.2 % 15,634 97.7 % $ 25,204 100.0 % $ 15,996 100.0 % Six Months Ended June 30, 2021 Six Months Ended June 30, 2020 (In thousands except percentages) Revenues Percent of Revenues Revenues Percent of Revenues Revenue recognized over time $ 1,098 2.6 % $ 555 1.7 % Revenue recognized at a point in time 41,838 97.4 % 31,870 98.3 % $ 42,936 100.0 % $ 32,425 100.0 % |
Summary of contract assets and contract liabilities | The following summarizes our contract assets and contract liabilities: (In thousands) June 30, 2021 December 31, 2020 Contract assets, included in other current assets $ 18 $ 2 Contract liabilities - advance customer payments $ 653 $ 567 Contract liabilities - deferred warranty revenue $ 391 $ 344 |
Summary of the amounts reclassified from beginning contract liabilities to revenue | The following summarizes the amounts reclassified from beginning contract liabilities to revenue: Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2021 2020 2021 2020 Amounts reclassified from beginning contract liabilities to revenue $ 120 $ 55 $ 345 $ 95 Amounts reclassified from deferred warranty revenue 98 83 161 183 T otal $ 218 $ 138 $ 506 $ 278 |
Marketable Securities (Tables)
Marketable Securities (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Marketable Securities [Abstract] | |
Schedule of Marketable Securities | Our investments in marketable securities are classified as available-for-sale and consist of the following: June 30, 2021 (In thousands) Cost Unrealized Unrealized Fair Value Short-Term U.S. government and agency obligations $ 3,332 $ 20 $ — $ 3,352 Corporate debt securities and certificates of deposit 3,882 15 — 3,897 Marketable securities – short-term $ 7,214 $ 35 $ — $ 7,249 Long-Term U.S. government and agency obligations $ 9,094 $ 30 $ (10 ) $ 9,114 Corporate debt securities and certificates of deposit 3,452 27 (1 ) 3,478 Asset backed securities 2,572 25 (1 ) 2,596 Equity security 42 — — 42 Marketable securities – long-term $ 15,160 $ 82 $ (12 ) $ 15,230 December 31, 2020 (In thousands) Cost Unrealized Unrealized Fair Value Short-Term U.S. government and agency obligations $ 4,817 $ 36 $ — $ 4,853 Corporate debt securities and certificates of deposit 3,113 21 — 3,134 Asset backed securities 133 1 — 134 Marketable securities – short-term $ 8,063 $ 58 $ — $ 8,121 Long-Term U.S. government and agency obligations $ 7,529 $ 66 $ — $ 7,595 Corporate debt securities and certificates of deposit 3,975 61 (1 ) 4,035 Asset backed securities 2,347 45 — 2,392 Equity security 42 — (12 ) 30 Marketable securities – long-term $ 13,893 $ 172 $ (13 ) $ 14,052 |
Schedule of Unrealized Loss Position | At June 30, 2021 and December 31, 2020, investments in marketable debt securities in an unrealized loss position were as follows: In Unrealized Loss Position For Less Than 12 Months In Unrealized Loss Position For Greater Than 12 Months (In thousands) Fair Value Gross Unrealized Fair Value Gross Unrealized Losses June 30, 2021 U.S. government and agency obligations $ 5,365 $ (10 ) $ — $ — Corporate debt securities and certificates of deposit 1,676 (1 ) — — Asset backed securities 549 (1 ) — — Marketable securities $ 7,590 $ (12 ) $ — $ — December 31, 2020 U.S. government and agency obligations $ 330 $ — $ — $ — Corporate debt securities and certificates of deposit 411 (1 ) — — Marketable securities $ 741 $ ( 1 ) $ — $ — |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements for Marketable Securities and Foreign Exchange Forward Contracts | The following provides information regarding fair value measurements for our marketable securities as of June 30, 2021 and December 31, 2020 according to the three Fair Value Measurements at June 30, 2021 (In thousands) Balance June 30, 2021 Quoted Prices 1 Significant 2 Significant 3 Marketable securities: U.S. government and agency obligations $ 12,466 $ — $ 12,466 $ — Corporate debt securities and certificates of deposit 7,375 — 7,375 — Asset backed securities 2,596 — 2,596 — Equity security 42 42 — — Total marketable securities $ 22,479 $ 42 $ 22,437 $ — Fair Value Measurements at December 31, 2020 (In thousands) Balance December 31, 2020 Quoted Prices 1 Significant 2 Significant 3 Marketable securities: U.S. government and agency obligations $ 12,448 $ — $ 12,448 $ — Corporate debt securities and certificates of deposit 7,169 — 7,169 — Asset backed securities 2,526 — 2,526 — Equity security 30 30 — — Total marketable securities $ 22,173 $ 30 $ 22,143 $ — |
Share-Based Compensation (Table
Share-Based Compensation (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Share-based Compensation [Abstract] | |
Schedule of Stock Option Activity | The following is a summary of stock option activity in the six months ended : Options Outstanding Weighted Average Exercise Outstanding, December 31, 2020 419,100 $ 15.22 Exercised (7,875 ) 17.09 Outstanding, June 30, 2021 411,225 $ 15.19 Exercisable, June 30, 2021 286,151 $ 12.90 |
Schedule of Non-Vested Restricted Stock Activity | The following is a summary of activity in restricted shares and restricted stock units in the : Restricted shares and restricted stock units Shares Weighted Average Grant Date Fair Value Non-vested at December 31, 2020 68,454 $ 21.45 Granted 8,000 27.96 Vested (4,000 ) 28.34 Non-vested at June 30, 2021 72,454 $ 21.79 |
Changes In Stockholders' Equi_2
Changes In Stockholders' Equity (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Stockholders' Equity Note [Abstract] | |
Schedule of changes in stockholders' equity | A reconciliation of the changes in our stockholders' equity is as follows: Three Months Ended June 30, 2021 Common Stock Accumulated Other Comprehensive Loss Retained Earnings Total Stockholders’ Equity (In thousands) Shares Amount Balance, March 31, 2021 7,299 $ 38,208 $ (1,306 ) $ 30,254 $ 67,156 Exercise of stock options, net of shares exchanged as payment 1 10 — — 10 Share issuances for director compensation 8 — — — — Share-based compensation — 337 — — 337 Other comprehensive loss, net of tax — — (21 ) — (21 ) Net income — — — 3,109 3,109 Balance, June 30, 2021 7,308 $ 38,555 $ (1,327 ) $ 33,363 $ 70,591 Six Months Ended June 30, 2021 Common Stock Accumulated Other Comprehensive Loss Retained Earnings Total Stockholders’ Equity (In thousands) Shares Amount Balance, December 31, 2020 7,295 $ 37,817 $ (1,102 ) $ 28,813 $ 65,528 Exercise of stock options, net of shares exchanged as payment 5 67 — — 67 Share issuances for director compensation 8 — — — — Share-based compensation — 671 — — 671 Other comprehensive loss, net of tax — — (225 ) — (225 ) Net income — — — 4,550 4,550 Balance, June 30, 2021 7,308 $ 38,555 $ (1,327 ) $ 33,363 $ 70,591 Three Months Ended June 30, 2020 : Common Stock Accumulated Other Comprehensive Loss Retained Earnings Total Stockholders’ Equity (In thousands) Shares Amount Balance, March 31, 2020 7,165 $ $ ) $ 23,915 $ 59,035 Exercise of stock options, net of shares exchanged as payment 75 171 — — 171 Tax payments for shares withheld related to stock option exercises (16 ) (420 ) — — (420 ) Share issuances for director compensation — — Share-based compensation 286 — Other comprehensive income, net of tax 250 — 250 Net income — 1,633 1,633 Balance, June 30, 2020 $ 37,053 $ (1,646 ) $ 25,548 $ 60,955 Six Months Ended June 30, 2020 : Common Stock Accumulated Other Comprehensive Loss Retained Earnings Total Stockholders’ Equity (In thousands) Shares Amount Balance, December 31, 2019 7,155 $ $ ) $ 23,071 $ 58,324 Exercise of stock options, net of shares exchanged as payment 85 256 — — 256 Tax payments for shares withheld related to stock option exercises (16 ) (420 ) — — (420 ) Share issuances for director compensation — — Share-based compensation 558 — Other comprehensive income, net of tax (240 ) — (240 ) Net income — 2,477 2,477 Balance, June 30, 2020 $ 37,053 $ (1,646 ) $ 25,548 $ 60,955 |
Other Financial Statement Data
Other Financial Statement Data (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Balance Sheet Related Disclosures [Abstract] | |
Schedule of Inventories | Inventories consisted of the following: (In thousands) June 30, 2021 December 31, 2020 Raw materials and purchased parts $ 14,106 $ 11,903 Work in process 2,103 2,459 Finished goods 5,603 4,208 Demonstration inventories, net 1,454 1,701 Total inventories $ 23,266 $ 20,271 |
Schedule of Accrued Liabilities | Accrued expenses consisted of the following: (In thousands) June 30, 2021 December 31, 2020 Wages and benefits $ 2,873 $ 2,768 Warranty liability 920 793 Income taxes payable 208 269 Other 164 63 Total accrued expenses $ 4,165 $ 3,893 |
Schedule of Changes In Estimated Warranty Liability | A reconciliation of the changes in our estimated warranty liability is as follows: Six Months Ended June 30, (In thousands) 2021 2020 Balance at beginning of period $ 839 $ 798 Accrual for warranties 527 429 Warranty revision 3 9 Settlements made during the period (392 ) (474 ) Balance at end of period 977 762 Current portion of estimated warranty liability (920 ) (729 ) Long-term estimated warranty liability $ 57 $ 33 |
Schedule Of Changes In Deferred Warranty Revenue | A reconciliation of the changes in our deferred warranty revenue is as follows: Six Months Ended June 30, (In thousands) 2021 2020 Balance at beginning of period $ 344 $ 275 Revenue deferrals 268 231 Amortization of deferred revenue (221 ) (183 ) Total deferred warranty revenue 391 323 Current portion of deferred warranty revenue (301 ) (209 ) Long-term deferred warranty revenue $ 90 $ 114 |
Intangible Assets (Tables)
Intangible Assets (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Intangible Assets, Net (Excluding Goodwill) [Abstract] | |
Schedule of Intangible Assets | Intangible assets consist of the following: June 30, 2021 December 31, 2020 (In thousands) Gross Accumulated Net Gross Accumulated Net Patents $ 1,991 $ (1,628 ) $ 363 $ 1,832 $ (1,542 ) $ 290 Software 206 (206 ) — 206 (200 ) 6 Marketing assets and customer relationships 86 (66 ) 20 101 (72 ) 29 Total intangible assets $ 2,283 $ (1,900 ) $ 383 $ 2,139 $ (1,814 ) $ 325 |
Schedule of Amortization Expense For Intangible Assets | Amortization expense in the three and six months ended June 30, 2021 and June 30, 2020 was as follows: Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2021 2020 2021 2020 Patents $ 44 $ 35 $ 87 $ 73 Software — 7 6 15 Marketing assets and customer relationships 2 3 4 5 Total amortization expense $ 46 $ 45 $ 97 $ 93 |
Revenue Concentrations, Signi_2
Revenue Concentrations, Significant Customers And Geographic Areas (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Segment Reporting [Abstract] | |
Summary Of Revenue By Product Line | The following summarizes our revenue by product line: Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2021 2020 2021 2020 High Precision 3D and 2D Sensors $ 7,131 $ 4,745 $ 13,488 $ 8,867 Inspection and Metrology Systems 12,581 7,661 18,920 16,022 Semiconductor Sensors 5,492 3,590 10,528 7,536 Total $ 25,204 $ 15,996 $ 42,936 $ 32,425 |
Schedule of Sales By Geographic Area | Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2021 2020 2021 2020 Americas $ 741 $ 97 $ 1,524 $ 497 Europe 3,017 2,369 6,518 4,472 China 8,545 3,954 13,709 7,834 Taiwan 943 763 1,673 2,479 Other Asia 7,541 5,449 11,683 9,129 Other 428 742 577 742 Total export sales $ 21,215 $ 13,374 $ 35,684 $ 25,153 |
Net Income Per Share (Tables)
Net Income Per Share (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Earnings Per Share [Abstract] | |
Schedule of Net Income per Basic and Diluted Shares | The components of net income per basic and diluted share were as follows: (In thousands except per share amounts) Net Income Weighted Average Shares Outstanding Per Share Amount Three Months Ended June 30, 2021 Basic $ 3,109 7,299 $ 0.43 Dilutive effect of common equivalent shares — 218 (0.02 ) Dilutive $ 3,109 7,517 $ 0.41 (In thousands except per share amounts) Net Income Weighted Average Shares Outstanding Per Share Amount Three Months Ended June 30, 2020 Basic $ 1,633 7,198 $ 0.23 Dilutive effect of common equivalent shares — 249 (0.01 ) Dilutive $ 1,633 7,447 $ 0.22 (In thousands except per share amounts) Net Income Weighted Average Shares Outstanding Per Share Amount Six Months Ended June 30, 2021 Basic $ 4,550 7,296 $ 0.62 Dilutive effect of common equivalent shares — 194 (0.01 ) Dilutive $ 4,550 7,490 $ 0.61 (In thousands except per share amounts) Net Income Weighted Average Shares Outstanding Per Share Amount Six Months Ended June 30, 2020 Basic $ 2,477 7,177 $ 0.35 Dilutive effect of common equivalent shares — 230 (0.02 ) Dilutive $ 2,477 7,407 $ 0.33 |
Other Comprehensive Income (L_2
Other Comprehensive Income (Loss) (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] | |
Effect of The Reclassifications From Comprehensive Income (Loss) To Earnings | Three Months Ended June 30, 2021 Three Months Ended June 30, 2020 (In thousands) Before Tax Tax Effect Net of Tax Amount Before Tax Tax Effect Net of Tax Amount Foreign currency translation adjustments $ 20 $ — $ 20 $ 154 $ — $ 154 Unrealized gains (losses) on available-for-sale securities (52 ) 11 (41 ) 121 (25 ) 96 Other comprehensive income (loss) $ (32 ) $ 11 $ (21 ) $ 275 $ (25 ) $ 250 Six Months Ended June 30, 2021 Six Months Ended June 30, 2020 (In thousands) Before Tax Tax Effect Net of Tax Amount Before Tax Tax Effect Net of Tax Amount Foreign currency translation adjustments $ (127 ) $ — $ (127 ) $ (446 ) $ — $ (446 ) Unrealized gains (losses) (124 ) 26 (98 ) 261 (55 ) 206 Other comprehensive loss $ (251 ) $ 26 $ (225 ) $ (185 ) $ (55 ) $ (240 ) |
Schedule of Accumulated Other Comprehensive Loss | At June 30, 2021 and 2020, components of accumulated other comprehensive loss is as follows: (In thousands) Foreign Available- for-Sale Accumulated Balances at December 31, 2020 $ (1,285 ) $ 183 $ (1,102 ) Other comprehensive loss for the six months ended June 30, 2021 (127 ) (98 ) (225 ) Balances at June 30, 2021 $ (1,412 ) $ 85 $ (1,327 ) (In thousands) Foreign Available- for-Sale Accumulated Balances at December 31, 2019 $ (1,475 ) $ 69 $ (1,406 ) Other comprehensive loss for the six months ended June 30, 2020 (446 ) 206 (240 ) Balances at June 30, 2020 $ (1,921 ) $ 275 $ (1,646 ) |
Covid-19 Pandemic (Narrative) (
Covid-19 Pandemic (Narrative) (Details) - USD ($) | 3 Months Ended | 6 Months Ended |
Jun. 30, 2020 | Jun. 30, 2020 | |
Singapore [Member] | Jobs Support Program [Member] | Reduced Employee Expenses [Member] | ||
Effects on Future Earnings and Cash Flows Resulting from Exit Plan [Line Items] | ||
Operating expenses | $ 276,000 | $ 295,000 |
Revenue Recognition (Summary Of
Revenue Recognition (Summary Of Revenue Performance Obligations) (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Performance Obligations | ||||
Revenues | $ 25,204 | $ 15,996 | $ 42,936 | $ 32,425 |
Percent of Revenues | 100.00% | 100.00% | 100.00% | 100.00% |
Revenue recognized over time [Member] | ||||
Performance Obligations | ||||
Revenues | $ 695 | $ 362 | $ 1,098 | $ 555 |
Percent of Revenues | 2.80% | 2.30% | 2.60% | 1.70% |
Revenue recognized at a point in time [Member] | ||||
Performance Obligations | ||||
Revenues | $ 24,509 | $ 15,634 | $ 41,838 | $ 31,870 |
Percent of Revenues | 97.20% | 97.70% | 97.40% | 98.30% |
Revenue Recognition (Schedule o
Revenue Recognition (Schedule of contract assets and contract liabilities) (Details) - USD ($) $ in Thousands | Jun. 30, 2021 | Dec. 31, 2020 |
Revenue Recognition [Abstract] | ||
Contract assets, included in other current assets | $ 18 | $ 2 |
Contract liabilities - advance customer payments | 653 | 567 |
Contract liabilities - deferred warranty revenue | $ 391 | $ 344 |
Revenue Recognition (Narrative)
Revenue Recognition (Narrative) (Details) - USD ($) | 6 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
REVENUE RECOGNITION | ||
Gain (Loss) on Sale of Assets and Asset Impairment Charges | $ 0 | $ 0 |
Minimum [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01 | ||
REVENUE RECOGNITION | ||
Period over which unsatisfied performance obligations are expected to be recognized | 1 year | |
Maximum [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01 | ||
REVENUE RECOGNITION | ||
Period over which unsatisfied performance obligations are expected to be recognized | 3 years |
Revenue Recognition (Summary _2
Revenue Recognition (Summary of the amounts reclassified from beginning contract liabilities to revenue) (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Revenue Recognition [Abstract] | ||||
Amounts reclassified from beginning contract liabilities to revenue | $ 120 | $ 55 | $ 345 | $ 95 |
Amounts reclassified from deferred warranty revenue | 98 | 83 | 161 | 183 |
Total | $ 218 | $ 138 | $ 506 | $ 278 |
Marketable Securities (Schedule
Marketable Securities (Schedule Of Marketable Securities) (Details) - USD ($) $ in Thousands | Jun. 30, 2021 | Dec. 31, 2020 |
Marketable securities - Short-Term | ||
Gain (Loss) on Investments [Line Items] | ||
Cost | $ 7,214 | $ 8,063 |
Unrealized Gains | 35 | 58 |
Unrealized Losses | 0 | 0 |
Fair Value | 7,249 | 8,121 |
Marketable securities - Short-Term | U.S. government and agency obligations | ||
Gain (Loss) on Investments [Line Items] | ||
Cost | 3,332 | 4,817 |
Unrealized Gains | 20 | 36 |
Unrealized Losses | 0 | 0 |
Fair Value | 3,352 | 4,853 |
Marketable securities - Short-Term | Corporate debt securities and certificates of deposit | ||
Gain (Loss) on Investments [Line Items] | ||
Cost | 3,882 | 3,113 |
Unrealized Gains | 15 | 21 |
Unrealized Losses | 0 | 0 |
Fair Value | 3,897 | 3,134 |
Marketable securities - Short-Term | Asset backed securities | ||
Gain (Loss) on Investments [Line Items] | ||
Cost | 133 | |
Unrealized Gains | 1 | |
Unrealized Losses | 0 | |
Fair Value | 134 | |
Marketable securities - Long-Term | ||
Gain (Loss) on Investments [Line Items] | ||
Cost | 15,160 | 13,893 |
Unrealized Gains | 82 | 172 |
Unrealized Losses | (12) | (13) |
Fair Value | 15,230 | 14,052 |
Marketable securities - Long-Term | U.S. government and agency obligations | ||
Gain (Loss) on Investments [Line Items] | ||
Cost | 9,094 | 7,529 |
Unrealized Gains | 30 | 66 |
Unrealized Losses | (10) | 0 |
Fair Value | 9,114 | 7,595 |
Marketable securities - Long-Term | Corporate debt securities and certificates of deposit | ||
Gain (Loss) on Investments [Line Items] | ||
Cost | 3,452 | 3,975 |
Unrealized Gains | 27 | 61 |
Unrealized Losses | (1) | (1) |
Fair Value | 3,478 | 4,035 |
Marketable securities - Long-Term | Asset backed securities | ||
Gain (Loss) on Investments [Line Items] | ||
Cost | 2,572 | 2,347 |
Unrealized Gains | 25 | 45 |
Unrealized Losses | (1) | 0 |
Fair Value | 2,596 | 2,392 |
Marketable securities - Long-Term | Equity security | ||
Gain (Loss) on Investments [Line Items] | ||
Cost | 42 | 42 |
Unrealized Gains | 0 | 0 |
Unrealized Losses | 0 | (12) |
Fair Value | $ 42 | $ 30 |
Marketable Securities (Schedu_2
Marketable Securities (Schedule Of Unrealized Loss Position) (Details) - USD ($) $ in Thousands | Jun. 30, 2021 | Dec. 31, 2020 |
Fair Value | ||
In Unrealized Loss Position For Less Than 12 Months | $ 7,590 | $ 741 |
In Unrealized Loss Position For Greater Than 12 Months | 0 | 0 |
Gross Unrealized Losses | ||
In Unrealized Loss Position For Less Than 12 Months | (12) | (1) |
In Unrealized Loss Position For Greater Than 12 Months | 0 | 0 |
U.S. government and agency obligations [Member] | ||
Fair Value | ||
In Unrealized Loss Position For Less Than 12 Months | 5,365 | 330 |
In Unrealized Loss Position For Greater Than 12 Months | 0 | 0 |
Gross Unrealized Losses | ||
In Unrealized Loss Position For Less Than 12 Months | (10) | 0 |
In Unrealized Loss Position For Greater Than 12 Months | 0 | 0 |
Corporate Debt Securities And Certificates Of Deposit [Member] | ||
Fair Value | ||
In Unrealized Loss Position For Less Than 12 Months | 1,676 | 411 |
In Unrealized Loss Position For Greater Than 12 Months | 0 | 0 |
Gross Unrealized Losses | ||
In Unrealized Loss Position For Less Than 12 Months | (1) | (1) |
In Unrealized Loss Position For Greater Than 12 Months | 0 | $ 0 |
Asset backed securities [Member] | ||
Fair Value | ||
In Unrealized Loss Position For Less Than 12 Months | 549 | |
In Unrealized Loss Position For Greater Than 12 Months | 0 | |
Gross Unrealized Losses | ||
In Unrealized Loss Position For Less Than 12 Months | (1) | |
In Unrealized Loss Position For Greater Than 12 Months | $ 0 |
Marketable Securities (Narrativ
Marketable Securities (Narrative) (Details) - USD ($) | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | Dec. 31, 2020 | |
Gain (Loss) on Investments [Line Items] | |||||
Maximum maturity of debt securities (less than 5 years) | 5 years | ||||
Accumulated pre-tax unrealized gains for marketable securities | $ 105,000 | $ 105,000 | $ 229,000 | ||
Proceeds from sales of available-for-sale marketable securities | 225,000 | $ 0 | 225,000 | $ 0 | |
Cost | $ 6,000,000 | 6,000,000 | 1,300,000 | ||
Unrealized gains or losses on marketable securities | $ 0 | $ 0 |
Marketable Securities (Schedu_3
Marketable Securities (Schedule Of Marketable Securities Classified As Cash Equivalents) (Details) - USD ($) | Jun. 30, 2021 | Dec. 31, 2020 |
Foreign Accounts | ||
Gain (Loss) on Investments [Line Items] | ||
Cash And Marketable Securities Held In Foreign Accounts | $ 1,400,000 | $ 672,000 |
Fair Value Measurements (Narrat
Fair Value Measurements (Narrative) (Details) - USD ($) | 6 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
Fair Value Disclosures [Abstract] | ||
Asset impairment charges | $ 0 | $ 0 |
Fair Value Measurements (Fair V
Fair Value Measurements (Fair Value Measurements For Marketable Securities And Foreign Exchange Forward Contracts) (Details) - USD ($) $ in Thousands | Jun. 30, 2021 | Dec. 31, 2020 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Marketable securities | $ 22,479 | $ 22,173 |
Quoted Prices In Active Markets For Identical Assets (Level 1) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Marketable securities | 42 | 30 |
Significant Other Observable Inputs (Level 2) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Marketable securities | 22,437 | 22,143 |
Significant Unobservable Inputs (Level 3) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Marketable securities | 0 | 0 |
U.S. government and agency obligations | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Marketable securities | 12,466 | 12,448 |
U.S. government and agency obligations | Quoted Prices In Active Markets For Identical Assets (Level 1) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Marketable securities | 0 | 0 |
U.S. government and agency obligations | Significant Other Observable Inputs (Level 2) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Marketable securities | 12,466 | 12,448 |
U.S. government and agency obligations | Significant Unobservable Inputs (Level 3) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Marketable securities | 0 | 0 |
Corporate debt securities and certificates of deposit | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Marketable securities | 7,375 | 7,169 |
Corporate debt securities and certificates of deposit | Quoted Prices In Active Markets For Identical Assets (Level 1) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Marketable securities | 0 | 0 |
Corporate debt securities and certificates of deposit | Significant Other Observable Inputs (Level 2) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Marketable securities | 7,375 | 7,169 |
Corporate debt securities and certificates of deposit | Significant Unobservable Inputs (Level 3) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Marketable securities | 0 | 0 |
Asset backed securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Marketable securities | 2,596 | 2,526 |
Asset backed securities | Quoted Prices In Active Markets For Identical Assets (Level 1) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Marketable securities | 0 | 0 |
Asset backed securities | Significant Other Observable Inputs (Level 2) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Marketable securities | 2,596 | 2,526 |
Asset backed securities | Significant Unobservable Inputs (Level 3) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Marketable securities | 0 | 0 |
Equity security | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Marketable securities | 42 | 30 |
Equity security | Quoted Prices In Active Markets For Identical Assets (Level 1) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Marketable securities | 42 | 30 |
Equity security | Significant Other Observable Inputs (Level 2) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Marketable securities | 0 | 0 |
Equity security | Significant Unobservable Inputs (Level 3) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Marketable securities | $ 0 | $ 0 |
Share-Based Compensation (Narra
Share-Based Compensation (Narrative) (Details) | May 13, 2021USD ($)$ / sharesshares | Jun. 30, 2021USD ($)qtrstock-based_complensation_planshares | Jun. 30, 2020USD ($) | Jun. 30, 2021USD ($)qtrstock-based_complensation_plan$ / sharesshares | Jun. 30, 2020USD ($)shares | Dec. 31, 2020shares |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Number of stock-based compensation plans | stock-based_complensation_plan | 3 | 3 | ||||
Common stock reserved for issuance pursuant to outstanding awards | 411,225 | 411,225 | 419,100 | |||
Weighted average grant date fair value (in dollars per share) | $ / shares | $ 27.96 | |||||
Number of shares vested | 4,000 | |||||
Aggregate fair value of outstanding restricted shares and restricted stock units | $ | $ 3,000,000 | $ 3,000,000 | ||||
Aggregate fair value of restricted shares and restricted stock units | $ | 115,000 | $ 102,000 | ||||
Proceeds from exercise of stock options | $ | $ 67,000 | $ 256,000 | ||||
Number of shares vested | 0 | 0 | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants, Forfeitures and Expirations in Period | 0 | |||||
Shares, Granted (in shares) | 8,000 | |||||
Unvested shares | 72,454 | 72,454 | 68,454 | |||
Equity based compensation expense | $ | $ 337,000 | $ 286,000 | $ 671,000 | $ 558,000 | ||
Unrecognized compensation cost related to non-vested equity based compensation | $ | $ 2,300,000 | $ 2,300,000 | ||||
Unrecognized equity based compensation weighted average period, years | 2 years 6 months 3 days | |||||
Stock Options | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Number of shares available for future issuance (in shares) | 124,501 | 124,501 | ||||
Common stock reserved for issuance pursuant to outstanding awards | 467,679 | 467,679 | ||||
Vesting period, years | 4 years | |||||
Expiration of stock options from date of grant | 7 years | |||||
Weighted average remaining contractual term, years | 3 years 1 month 13 days | |||||
Aggregate intrinsic value for all options outstanding | $ | $ 10,600,000 | $ 10,600,000 | ||||
Weighted average remaining contractual term for exercisable options, years | 2 years 2 months 4 days | |||||
Aggregate intrinsic value of exercisable options | $ | 8,000,000 | $ 8,000,000 | ||||
Aggregate intrinsic value of stock options exercised | $ | 87,000 | 2,100,000 | ||||
Proceeds from exercise of stock options | $ | 67,000 | 256,000 | ||||
Equity based compensation expense | $ | 125,000 | 114,000 | $ 248,000 | 228,000 | ||
Restricted Shares | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Shares, Granted (in shares) | 8,000 | |||||
Restricted Stock Units (RSUs) | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Vesting period, years | 4 years | |||||
Restricted stock units to common stock ratio, shares entitled, shares | 1 | |||||
Shares, Granted (in shares) | 0 | |||||
Equity based compensation expense | $ | $ 124,000 | 101,000 | $ 247,000 | 202,000 | ||
Employee Stock Purchase Plan | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Number of shares available for future issuance (in shares) | 136,971 | 136,971 | ||||
Maximum contribution per plan year | $ | $ 6,500 | |||||
Equity based compensation expense | $ | $ 31,000 | 25,000 | $ 63,000 | 48,000 | ||
Employees can purchase stock at the percentage rate of the lower of the market price on the first or last day of the offering period (as a percent) | 85.00% | |||||
Employee Stock Purchase Plan | Minimum | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Payroll deduction for employee stock purchase plan percentage | 1.00% | |||||
Employee Stock Purchase Plan | Maximum | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Payroll deduction for employee stock purchase plan percentage | 10.00% | |||||
Non Employee Director Stock Plan [Member] | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Number of shares available for future issuance (in shares) | 36,000 | 36,000 | ||||
Common stock reserved for issuance pursuant to outstanding awards | 8,000 | 8,000 | ||||
Number of shares granted for non-employee directors upon re-election, shares | 2,000 | |||||
Number of quarterly installments in which awards will vest | qtr | 4 | 4 | ||||
Stock issued during period, shares | 8,000 | |||||
Stock granted, value | $ | $ 224,000 | |||||
Weighted average grant date fair value (in dollars per share) | $ / shares | $ 27.96 | |||||
Number of shares vested | 0 | |||||
Unvested shares | 8,000 | 8,000 | ||||
Aggregate fair value of the unvested shares based on the closing price of entity's common stock | $ | $ 328,000 | $ 328,000 | ||||
Equity based compensation expense | $ | $ 57,000 | $ 46,000 | $ 113,000 | $ 80,000 |
Share-Based Compensation (Sched
Share-Based Compensation (Schedule Of Stock Option Activity) (Details) - $ / shares | 6 Months Ended |
Jun. 30, 2021 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] | |
Options Outstanding, Outstanding, December 31, 2020 (in shares) | 419,100 |
Options Outstanding, Exercised (in shares) | (7,875) |
Options Outstanding, Outstanding, June 30, 2021 (in shares) | 411,225 |
Options Outstanding, Exercisable, June 30, 2021 (in shares) | 286,151 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] | |
Weighted-Average Exercise Price Per Share, Outstanding, December 31, 2020 (in dollars per share) | $ 15.22 |
Weighted-Average Exercise Price Per Share, Exercised (in dollars per share) | 17.09 |
Weighted-Average Exercise Price Per Share, Outstanding, June 30, 2021 (in dollars per share) | 15.19 |
Weighted-Average Exercise Price Per Share, Exercisable, June 30, 2021 (in dollars per share) | $ 12.90 |
Share-Based Compensation (Sch_2
Share-Based Compensation (Schedule Of Non-Vested Restricted Stock Activity) (Details) | 6 Months Ended |
Jun. 30, 2021$ / sharesshares | |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] | |
Shares, Non-vested at December 31, 2020 (in shares) | shares | 68,454 |
Shares, Granted (in shares) | shares | 8,000 |
Shares, Vested (in shares) | shares | (4,000) |
Shares, Non-vested at June 30, 2021 (in shares) | shares | 72,454 |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] | |
Weighted Average Grant Date Fair Value, Non-vested at December 31, 2020 (in dollars per share) | $ / shares | $ 21.45 |
Weighted Average Grant Date Fair Value, Granted (in dollars per share) | $ / shares | 27.96 |
Weighted Average Grant Date Fair Value, Vested (in dollars per share) | $ / shares | 28.34 |
Weighted Average Grant Date Fair Value, Non-vested at June 30, 2021 (in dollars per share) | $ / shares | $ 21.79 |
Changes In Stockholders' Equi_3
Changes In Stockholders' Equity (Schedule of Changes in Stockholders' Equity) (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||
BALANCE | $ 67,156 | $ 59,035 | $ 65,528 | $ 58,324 |
BALANCE, shares | 7,294,617 | |||
Exercise of stock options, net of shares exchanged as payment | 10 | 171 | $ 67 | 256 |
Exercise of stock options, net of shares exchanged as payment, shares | 7,875 | |||
Tax payments for shares withheld related to stock option exercises | (420) | (420) | ||
Share issuances for director compensation | 0 | 0 | $ 0 | 0 |
Share-based compensation | 337 | 286 | 671 | 558 |
Other comprehensive income (loss), net of tax | (21) | 250 | (225) | (240) |
Net income | 3,109 | 1,633 | 4,550 | 2,477 |
BALANCE | $ 70,591 | 60,955 | $ 70,591 | 60,955 |
BALANCE, shares | 7,308,001 | 7,308,001 | ||
Common Stock [Member] | ||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||
BALANCE | $ 38,208 | $ 37,016 | $ 37,817 | $ 36,659 |
BALANCE, shares | 7,299,000 | 7,165,000 | 7,295,000 | 7,155,000 |
Exercise of stock options, net of shares exchanged as payment | $ 10 | $ 171 | $ 67 | $ 256 |
Exercise of stock options, net of shares exchanged as payment, shares | 1,000 | 75,000 | 5,000 | 85,000 |
Tax payments for shares withheld related to stock option exercises | $ (420) | $ (420) | ||
Tax payments for shares withheld related to stock option exercises (in shares) | 16,000 | 16,000 | ||
Share issuances for director compensation | $ 0 | $ 0 | $ 0 | $ 0 |
Share issuances for director compensation, shares | 8,000 | 8,000 | 8,000 | 8,000 |
Share-based compensation | $ 337 | $ 286 | $ 671 | $ 558 |
Other comprehensive income (loss), net of tax | 0 | 0 | 0 | 0 |
Net income | 0 | 0 | 0 | 0 |
BALANCE | $ 38,555 | $ 37,053 | $ 38,555 | $ 37,053 |
BALANCE, shares | 7,308,000 | 7,232,000 | 7,308,000 | 7,232,000 |
Accumulated Other Comprehensive Loss [Member] | ||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||
BALANCE | $ (1,306) | $ (1,896) | $ (1,102) | $ (1,406) |
Exercise of stock options, net of shares exchanged as payment | 0 | 0 | 0 | 0 |
Tax payments for shares withheld related to stock option exercises | 0 | 0 | ||
Share issuances for director compensation | 0 | 0 | 0 | 0 |
Share-based compensation | 0 | 0 | 0 | 0 |
Other comprehensive income (loss), net of tax | (21) | 250 | (225) | (240) |
Net income | 0 | 0 | 0 | 0 |
BALANCE | (1,327) | (1,646) | (1,327) | (1,646) |
Retained Earnings [Member] | ||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||
BALANCE | 30,254 | 23,915 | 28,813 | 23,071 |
Exercise of stock options, net of shares exchanged as payment | 0 | 0 | 0 | 0 |
Tax payments for shares withheld related to stock option exercises | 0 | 0 | ||
Share issuances for director compensation | 0 | 0 | 0 | 0 |
Share-based compensation | 0 | 0 | 0 | 0 |
Other comprehensive income (loss), net of tax | 0 | 0 | 0 | 0 |
Net income | 3,109 | 1,633 | 4,550 | 2,477 |
BALANCE | $ 33,363 | $ 25,548 | $ 33,363 | $ 25,548 |
Other Financial Statement Dat_2
Other Financial Statement Data (Schedule Of Inventories) (Details) - USD ($) $ in Thousands | Jun. 30, 2021 | Dec. 31, 2020 |
Balance Sheet Related Disclosures [Abstract] | ||
Raw materials and purchased parts | $ 14,106 | $ 11,903 |
Work in process | 2,103 | 2,459 |
Finished goods | 5,603 | 4,208 |
Demonstration inventories, net | 1,454 | 1,701 |
Total inventories | $ 23,266 | $ 20,271 |
Other Financial Statement Dat_3
Other Financial Statement Data (Narrative) (Details) - USD ($) | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | Dec. 31, 2020 | |
Inventory [Line Items] | |||||
Demonstration inventory useful life (in months) | 36 months | ||||
Accumulated amortization for demonstration inventories | $ 2,600,000 | $ 2,600,000 | $ 2,700,000 | ||
Amortization expense related to demonstration inventories | $ 168,000 | $ 211,000 | $ 322,000 | $ 442,000 | |
Minimum | |||||
Inventory [Line Items] | |||||
Product warranties time frame, years | 1 year | ||||
Maximum | |||||
Inventory [Line Items] | |||||
Product warranties time frame, years | 3 years |
Other Financial Statement Dat_4
Other Financial Statement Data (Schedule Of Accrued Expenses) (Details) - USD ($) $ in Thousands | Jun. 30, 2021 | Dec. 31, 2020 | Jun. 30, 2020 |
Balance Sheet Related Disclosures [Abstract] | |||
Wages and benefits | $ 2,873 | $ 2,768 | |
Warranty liability | 920 | 793 | $ 729 |
Income taxes payable | 208 | 269 | |
Other | 164 | 63 | |
Accrued expenses | $ 4,165 | $ 3,893 |
Other Financial Statement Dat_5
Other Financial Statement Data (Schedule Of Changes In Estimated Warranty Liability) (Details) - USD ($) $ in Thousands | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Dec. 31, 2020 | |
Movement in Standard Product Warranty Accrual [Roll Forward] | |||
Balance at beginning of period | $ 839 | $ 798 | |
Accrual for warranties | 527 | 429 | |
Warranty revision | 3 | 9 | |
Settlements made during the period | (392) | (474) | |
Balance at end of period | 977 | 762 | |
Current portion of estimated warranty liability | (920) | (729) | $ (793) |
Long-term estimated warranty liability | $ 57 | $ 33 |
Other Financial Statement Dat_6
Other Financial Statement Data (Schedule Of Changes In Deferred Warranty Revenue) (Details) - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
Movement in Extended Product Warranty Accrual [Roll Forward] | ||
Balance at beginning of period | $ 344 | $ 275 |
Revenue deferrals | 268 | 231 |
Amortization of deferred revenue | (221) | (183) |
Total deferred warranty revenue | 391 | 323 |
Current portion of deferred warranty revenue | (301) | (209) |
Long-term deferred warranty revenue | $ 90 | $ 114 |
Intangible Assets (Schedule Of
Intangible Assets (Schedule Of Intangible Assets) (Details) - USD ($) $ in Thousands | Jun. 30, 2021 | Dec. 31, 2020 |
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | $ 2,283 | $ 2,139 |
Accumulated Amortization | (1,900) | (1,814) |
Net | 383 | 325 |
Patents | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | 1,991 | 1,832 |
Accumulated Amortization | (1,628) | (1,542) |
Net | 363 | 290 |
Software | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | 206 | 206 |
Accumulated Amortization | (206) | (200) |
Net | 0 | 6 |
Marketing assets and customer relationships | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | 86 | 101 |
Accumulated Amortization | (66) | (72) |
Net | $ 20 | $ 29 |
Intangible Assets (Schedule O_2
Intangible Assets (Schedule Of Amortization Expense For Intangible Assets) (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Finite-Lived Intangible Assets [Line Items] | ||||
Amortization of intangibles | $ 46 | $ 45 | $ 97 | $ 93 |
Patents | ||||
Finite-Lived Intangible Assets [Line Items] | ||||
Amortization of intangibles | 44 | 35 | 87 | 73 |
Software | ||||
Finite-Lived Intangible Assets [Line Items] | ||||
Amortization of intangibles | 0 | 7 | 6 | 15 |
Marketing assets and customer relationships | ||||
Finite-Lived Intangible Assets [Line Items] | ||||
Amortization of intangibles | $ 2 | $ 3 | $ 4 | $ 5 |
Intangible Assets (Narrative) (
Intangible Assets (Narrative) (Details) | Jun. 30, 2021USD ($) |
Intangible Assets, Net (Excluding Goodwill) [Abstract] | |
Amortization expense, remainder of 2021 | $ 96,000 |
Amortization expense, 2022 | 158,000 |
Amortization expense, 2023 | 109,000 |
Amortization expense, 2024 | $ 20,000 |
Revenue Concentrations, Signi_3
Revenue Concentrations, Significant Customers, and Geographic Areas (Summary Of Revenue By Product Line) (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Concentration Risk [Line Items] | ||||
Revenues | $ 25,204 | $ 15,996 | $ 42,936 | $ 32,425 |
High Precision 3D and 2D Sensors [Member] | ||||
Concentration Risk [Line Items] | ||||
Revenues | 7,131 | 4,745 | 13,488 | 8,867 |
Inspection and Metrology Systems [Member] | ||||
Concentration Risk [Line Items] | ||||
Revenues | 12,581 | 7,661 | 18,920 | 16,022 |
Semiconductor Sensors [Member] | ||||
Concentration Risk [Line Items] | ||||
Revenues | $ 5,492 | $ 3,590 | $ 10,528 | $ 7,536 |
Revenue Concentrations, Signi_4
Revenue Concentrations, Significant Customers And Geographic Areas (Narrative) (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Revenue, Major Customer [Line Items] | ||||
Revenue, export sales percentage | 84.00% | 84.00% | 83.00% | 78.00% |
Customer Concentration Risk | Sales Revenue, net | Significant Customer A [Member] | ||||
Revenue, Major Customer [Line Items] | ||||
Concentration risk percentage | 19.00% | |||
Customer Concentration Risk | Accounts Receivable | Significant Customer A [Member] | ||||
Revenue, Major Customer [Line Items] | ||||
Accounts receivable, net | $ 2.4 | $ 2.4 |
Revenue Concentrations, Signi_5
Revenue Concentrations, Significant Customers And Geographic Areas (Schedule Of Sales By Geographic Area) (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Revenue, Major Customer [Line Items] | ||||
Total export sales | $ 21,215 | $ 13,374 | $ 35,684 | $ 25,153 |
Americas | ||||
Revenue, Major Customer [Line Items] | ||||
Total export sales | 741 | 97 | 1,524 | 497 |
Europe | ||||
Revenue, Major Customer [Line Items] | ||||
Total export sales | 3,017 | 2,369 | 6,518 | 4,472 |
China | ||||
Revenue, Major Customer [Line Items] | ||||
Total export sales | 8,545 | 3,954 | 13,709 | 7,834 |
Taiwan | ||||
Revenue, Major Customer [Line Items] | ||||
Total export sales | 943 | 763 | 1,673 | 2,479 |
Other Asia | ||||
Revenue, Major Customer [Line Items] | ||||
Total export sales | 7,541 | 5,449 | 11,683 | 9,129 |
Other | ||||
Revenue, Major Customer [Line Items] | ||||
Total export sales | $ 428 | $ 742 | $ 577 | $ 742 |
Net Income Per Share (Schedule
Net Income Per Share (Schedule of Net Income per Basic and Diluted Shares) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Earnings Per Share [Abstract] | ||||
Net income | $ 3,109 | $ 1,633 | $ 4,550 | $ 2,477 |
Weighted Average Shares Outstanding, Basic (in shares) | 7,299 | 7,198 | 7,296 | 7,177 |
Per Share Amount, Basic (in dollars per share) | $ 0.43 | $ 0.23 | $ 0.62 | $ 0.35 |
Weighted Average Shares Outstanding, Dilutive effect of common equivalent shares (in shares) | 218 | 249 | 194 | 230 |
Per Share Amount, Dilutive effect of common equivalent shares (in usd per share) | $ (0.02) | $ (0.01) | $ (0.01) | $ (0.02) |
Weighted Average Shares Outstanding, Dilutive (in shares) | 7,517 | 7,447 | 7,490 | 7,407 |
Per Share Amount, Dilutive (in dollars per share) | $ 0.41 | $ 0.22 | $ 0.61 | $ 0.33 |
Net Income Per Share (Narrative
Net Income Per Share (Narrative) (Details) - shares | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Earnings Per Share [Abstract] | ||||
Earnings per share, potentially dilutive shares (in shares) | 47,000 | 34,000 | 72,000 | 89,000 |
Other Comprehensive Income (L_3
Other Comprehensive Income (Loss) (The Effect Of The Reclassifications From Other Comprehensive Income (Loss) To Earnings) (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||
Foreign currency translation adjustments, Before Tax | $ 20 | $ 154 | $ (127) | $ (446) |
Foreign currency translation adjustments, Tax | 0 | 0 | 0 | 0 |
Foreign currency translation adjustments, Net of Tax | 20 | 154 | (127) | (446) |
Unrealized gains (losses) on available-for-sale securities, Before Tax | (52) | 121 | (124) | 261 |
Unrealized gains (losses) on available-for-sale securities, Tax | 11 | (25) | 26 | (55) |
Unrealized gains (losses) on available-for-sale securities, Net of Tax | (41) | 96 | (98) | 206 |
Total other comprehensive income (loss) before income taxes | (32) | 275 | (251) | (185) |
Other comprehensive income (loss), Tax | 11 | (25) | 26 | (55) |
Total other comprehensive income (loss) after income taxes | $ (21) | $ 250 | $ (225) | $ (240) |
Other Comprehensive Income (L_4
Other Comprehensive Income (Loss) (Schedule Of Accumulated Other Comprehensive Loss) (Details) - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
AOCI Attributable to Parent, Net of Tax [Roll Forward] | ||
Balance | $ (1,102) | $ (1,406) |
Other comprehensive loss | (225) | (240) |
Balance | (1,327) | (1,646) |
Foreign Currency Translation Adjustments | ||
AOCI Attributable to Parent, Net of Tax [Roll Forward] | ||
Balance | (1,285) | (1,475) |
Other comprehensive loss | (127) | (446) |
Balance | (1,412) | (1,921) |
Available-for-sale Securities | ||
AOCI Attributable to Parent, Net of Tax [Roll Forward] | ||
Balance | 183 | 69 |
Other comprehensive loss | (98) | 206 |
Balance | $ 85 | $ 275 |
Income Taxes (Details)
Income Taxes (Details) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Income Tax Examination [Line Items] | ||||
Income tax expense (benefit) | $ 590,000 | $ (96,000) | $ 901,000 | $ 53,000 |
Effective income tax rate (as a percent) | 17.00% | 2.00% | ||
Excess tax benefits from employee stock option exercises | $ 340,000 | $ 356,000 | ||
Need for valuation allowance based on history of cumulative losses | 3 years |